Can Lymphatic Filariasis Be Eliminated by 2020?

M. Rebollo,M. Bockarie

DOI: https://doi.org/10.1016/j.pt.2016.09.009

2017-02-01

Trends in Parasitology

Abstract:

What problem does this paper attempt to address?

Pembrolizumab Plus Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma

Editorial Staff

DOI: https://doi.org/10.55627/mmc.003.02.0461

2023-12-29

Molecular Medicine Communications

Abstract:he combination of pembrolizumab, and trastuzumab chemotherapy has long been investigated in the treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. HER2-positive gastric or gastroesophageal junction adenocarcinoma refers to cancers that overexpress the human epidermal growth factor receptor 2 (HER2), which is associated with more aggressive tumor behavior. Pembrolizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, a checkpoint protein on immune cells. By blocking PD-1, pembrolizumab helps unleash the immune system to target and attack cancer cells. Trastuzumab is another monoclonal antibody that specifically targets HER2-positive cancer cells. It has been a standard treatment for HER2-positive breast cancer and has been explored in HER2-positive gastric and gastroesophageal junction cancers. Janjigian and colleagues revealed the interim analysis of a randomized, phase 3 KEYNOTE-811 trial which involved 168 medical centers in 20 countries worldwide. They found that compared with placebo, pembrolizumab significantly improved progression-free survival when combined with first-line trastuzumab and chemotherapy for metastatic HER2-positive gastro-oesophageal cancer, specifically in patients with tumors with a PD-L1 combined positive score of 1 or more. They stated that the overall survival follow-up is ongoing and will be reported at the final analysis. Lancet. 2023 Dec 9;402(10418):2197-2208. doi: 10.1016/S0140-6736(23)02033-0.
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial

Jifang Gong,Tianshu Liu,Qingxia Fan,Li Bai,Feng Bi,Shukui Qin,Jinwan Wang,Nong Xu,Ying Cheng,Yuxian Bai,Wei Liu,Liwei Wang,Lin Shen

DOI: https://doi.org/10.1186/s12885-016-2092-9

IF: 4.638

2016-01-01

BMC Cancer

Abstract:Background The ToGA study showed that trastuzumab plus chemotherapy prolonged median survival in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. Among chemotherapy options, oxaliplatin might be as effective as cisplatin but has shown to be more tolerable. To further improve treatment options for patients with advanced gastric cancer, we initiated a study to evaluate the efficacy and safety of trastuzumab plus oxaliplatin/capecitabine in patients with HER2-positive advanced gastric cancer. Methods CGOG1001 was an open-label, multicenter, prospective phase II study. Patients with chemotherapy-naive HER2-positive advanced gastric cancer were eligible. Trastuzumab was administered at a loading dose of 8 mg/kg followed by 6 mg/kg infusion every 3 weeks (q3w). Oxaliplatin was administrated as a 130 mg/m 2 infusion, q3w, for up to 6 cycles. Capecitabine 1000 mg/m 2 was given orally twice daily on days 1–14 followed by a 7-day rest interval. Trastuzumab and capecitabine were continued until disease progression or intolerable toxicity. The primary endpoint was objective response rate. Simon two-stage design (H 0 = 40 %, H 1 = 60 %, α = 0.05, β = 0.2) by Response Evaluation Criteria In Solid Tumors 1.0 was applied. Results Fifty-one patients were enrolled. Confirmed response was recorded in 46 patients. One patient achieved complete response and 33 patients achieved partial response (response rate 34/51 [66.7 %] in the intent-to-treat population). Median follow-up time was 28.6 months, with a median progression-free survival of 9.2 months (95 % confidence interval [CI]: 6.5–11.6) and a median overall survival (OS) of 19.5 months (95 % CI: 15.5–26.0). Patients with a HER2/CEP17 ratio of greater than five achieved improved OS (20.9 vs 19.5 months, p = 0.001). The most common adverse events of grade 3 or above were thrombocytopenia (21.6 %), neutropenia (13.7 %), anemia (5.9 %) and leucopenia (3.9 %). Conclusion The addition of trastuzumab to oxaliplatin/capecitabine was well tolerated and the results demonstrated encouraging efficacy. Trial registration ClinicalTrials.gov NCT01364493 .
Targeted Therapies in Advanced Gastric Cancer

Timil H. Patel,Michael Cecchini

DOI: https://doi.org/10.1007/s11864-020-00774-4

2020-07-28

Current Treatment Options in Oncology

Abstract:Despite a decreasing incidence in the USA, gastric cancer is highly prevalent worldwide. Furthermore, gastric cancer remains highly lethal with median survival of less than 1 year for metastatic disease. The backbone of therapy against metastatic gastric cancer remains cytotoxic chemotherapy, but recent advances in the molecular understanding of gastric cancer have renewed hope within that targeted agents can be leveraged to improve survival and reduce toxicity. For example, in patients with human epidermal growth factor-2 (HER2)-positive gastric cancer, the addition of trastuzumab to frontline chemotherapy improves survival. In the second line, oncologists can now administer a vascular endothelial growth factor (VEGF) receptor inhibitor, ramucirumab, as a single agent or in combination with chemotherapy, and the immune checkpoint inhibitor pembrolizumab is approved in multiple settings dependent on the Programmed Death Ligand 1 (PD-L1) status. For patients with metastatic disease, our approach to standard of care in the first-line setting is a 5FU/platinum doublet with trastuzumab for HER2-positive tumors. In the second-line setting, most patients receive ramucirumab + paclitaxel, but those that are MSI high receive pembrolizumab. For squamous cell carcinoma of the esophagus with high PD-L1 status (combined positive score (CPS) ≥ 10), we recommend pembrolizumab in the second line. While for PD-L1 ≥ 1% gastroesophageal adenocarcinoma, we do not recommend pembrolizumab before the third-line setting, although this may change in the near future for CPS ≥ 10. The future landscape for targeted therapy in gastric cancer is promising. Numerous clinical trials evaluating the combination immune therapy with molecularly targeted agents are generating much excitement. Moreover, genomic data from The Cancer Center Genome (TCGA) and Asian Cancer Research Group (ACRG) classifications is being used to identify molecular subtypes to enable future clinical trials to include biomarker-enriched patient populations.

oncology
Abstract 5129: Clinical implication of plasma ctDNA features in HER2-positive gastric cancer treated with combinations of trastuzumab & anti-PD-1 agents

Xiaoyi Chong,Zhengqing Yan,Hua Liu,Lin Cong,Fangli Jiang,Chenhui Xu,Yan Li,Hui Chen,Yanyan Li,Congcong Ji,Shiqing Chen,Xiaochen Zhao,Xiaotian Zhang

DOI: https://doi.org/10.1158/1538-7445.am2022-5129

IF: 11.2

2022-06-17

Cancer Research

Abstract:PURPOSE:Previous studies supported combining PD-1 inhibitors with trastuzumab to treat HER2-positive cancers. Yet proper biomarkers for response/resistance prediction remain unveiled. METHODS: Eligible patients were 18 years of age or older and had histologically confirmed gastric cancer (GC) or gastro-esophageal junction cancer (GEJ). The HER2 status was evaluated with tissue assay, including IHC and FISH. Paired plasma-white blood cell samples were collected prior treatment and assessed with targeted next-generation sequencing (NGS) of circulating tumor DNA (ctDNA). Different therapeutic regimens and ctDNA biomarkers were explored in HER2-positive patients, who received combining therapeutics containing trastuzumab and anti-PD-1 agents. The HER2-positive status was defined as IHC 3+ or IHC 2+/FISH-positive. RESULTS: A total of 49 patients were included. Four patients were excluded due to fail in the quality control for NGS. The HER2 status of tumor tissue and matched plasma ctDNA at baseline display a high concordance of 84.4% (38/45). NGS ctDNA method demonstrated an 84.2% (33/40) sensitivity and a 100% (5/5) specificity to detect HER2 amplification. Among HER2-positive patients, nineteen and eighteen patients were administrated trastuzumab+anti-PD-1±anti-vascular (chemo-free) and trastuzumab+anti-PD-1+chemotherapy (chemo-containing) respectively. Compared to Chemo-free subgroup, the chemo-containing subgroup had numerically higher ORR (61.11% vs 31.58%, p = 0.10) and longer median PFS (8.98 vs 5.43 months, p = 0.54, HR 0.78, 95%CI: 0.35-1.73). Patients with HER2 amplification in ctDNA had higher ORR than those without amplification (56.67% vs 0%, p = 0.009). Besides, an immune-related negative gene set (PTEN mutations, MDM2 amplification and FGF3/4/19 amplification) was also explored. The patients carrying immune-related negative gene alterations achieved decreased ORR (0% vs 54.8%, p = 0.02) and shorter PFS (2.1 vs 6.9 months, p<0.0001, HR 8.21, 95%CI: 2.76-24.48), compared to that of wild type. CONCLUSIONS: The ctDNA display a high consistency with tumor tissue for HER2 status. Compared to chemo-free regimens, chemo-containing regimens trend to demonstrate improved PFS and ORR in HER2-postive GC/GEJ, though no statistically significant. The HER2 amplification and immune-related negative gene alterations in ctDNA might be used as alternative biomarkers for predicting the efficacy of combining therapeutics containing trastuzumab and anti-PD-1 agents. Further studies are warranted to confirm our observation for better management of HER2-positive GC/GEJ. Citation Format: Xiaoyi Chong, Zhengqing Yan, Hua Liu, Lin Cong, Fangli Jiang, Chenhui Xu, Yan Li, Hui Chen, Yanyan Li, Congcong Ji, Shiqing Chen, Xiaochen Zhao, Xiaotian Zhang. Clinical implication of plasma ctDNA features in HER2-positive gastric cancer treated with combinations of trastuzumab & anti-PD-1 agents [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 5129.

oncology
Immune checkpoint inhibitors combined with HER-2 targeted therapy in HER-2 positive gastroesophageal cancer

Adilai Aisa,Shanshan Weng,Xinyu Li,Ding Zhang,Ying Yuan

DOI: https://doi.org/10.1016/j.critrevonc.2022.103864

IF: 6.625

2022-01-01

Critical Reviews in Oncology/Hematology

Abstract:GEC is one of the most common cancers and has become a significant health burden worldwide. HER-2 is a protooncogene, amplified or overexpressed in different tumors, and associated with a worse prognosis. Trastuzumab plus chemotherapy is the current standard treatment for advanced HER-2 positive GEC. However, it still does not benefit well all patients. HER-2 targeted therapy can up-regulate the expression of PD-1, CTL-4, and TAMs in the tumor microenvironment, strengthen the ADCC process, and enhance the efficacy of immunotherapy. While immune checkpoint inhibitors could reduce drug resistance to anti-HER-2 drugs. Moreover, immunotherapy combined with HER-2 targeted therapy in HER-2 positive GEC has shown perceptible efficacy and acceptable side effects in clinical trials and is regarded as a new therapeutic strategy for GEC. However, there remain significant challenges and requires more research to improve the survival benefit of this therapeutic approach.
Trastuzumab Plus Docetaxel And Capecitabine As A First-Line Treatment For Her2-Positive Advanced Gastric Or Gastroesophageal Junction Cancer: A Phase Ii, Multicenter, Open-Label, Single-Arm Study

Feng Wang,Tian-Shu Liu,Xiang-Lin Yuan,Hui-Yan Luo,Kang-Sheng Gu,Ying Yuan,Yan-Hong Deng,Jian-Ming Xu,Yu-Xian Bai,Ying Wang,Wang-Jun Liao,He-Long Zhang,Feng Bi,Bang-Mao Wang,Zhi-Xiang Zhuang,Teng-Jia Jiang,Rui-Hua Xu

2020-01-01

American journal of cancer research

Abstract:Gastric cancer (GC) is the second most common cancer in China. The ToGA study showed that trastuzumab in combination with fluoropyrimidine plus cisplatin prolonged overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced GC (AGC). However, some patients may not be able to receive this regimen. We conducted a clinical study to evaluate the efficacy and safety of trastuzumab in combination with docetaxel+capecitabine (DX) in patients with HER2-positive AGC. This phase II, multi-center, open-label, single arm study enrolled patients with HER2-positive AGC who had not received prior treatment for metastatic disease. Patients were treated with a regimen of trastuzumab (8 mg/kg loading dose followed by 6 mg/kg, day 1), capecitabine (1000 mg/m(2) twice daily, days 1-14) and docetaxel (60 mg/m(2), day 1 for 6 cycles) every 3 weeks. The primary endpoint was progression-free survival (PFS) and the secondary endpoints were objective response rate (ORR), OS and safety profiles. Sixty-seven patients with AGC were enrolled from 14 centers. 64 were included in the full analysis set (FAS). The median PFS was 8.1 months (95% confidence interval [CI]: 5.6-12.8) and the median OS was 20.9 months (95% CI: 15.1-33.0). Response was evaluated in 59 patients. The ORR was 67.8%. The most common adverse events of Grade >= 3 were neutropenia, leukopenia, hand-foot syndrome, febrile neutropenia and anemia. We concluded that combination treatment with trastuzumab and DX was well-tolerated and highly effective in patients with HER2-positive AGC, and may offer an alternative to current treatments.
Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells in Vitro and in Vivo

Wei Wang,Zhenhua Hu,Yu Huang,Huilin Zheng,Qiang Sun,Qifan Yang,Yuan Zhang,Linshi Zhang,Weilin Wang

DOI: https://doi.org/10.1155/2019/9205851

2019-01-01

BioMed Research International

Abstract:The effects of standard clinical therapies including surgery and chemotherapy are poor in advanced gallbladder cancer (GBC). There are a few reported cases of human epidermal growth factor receptor 2 (HER2)-positive GBC that responded well to trastuzumab. But trastuzumab has not yet been used to treat HER2-negative GBC. In this study, we investigated the cytotoxic effects of different combined therapies with trastuzumab and gemcitabine and/or 5-fluorouracil on HER2-negative GBC cell lines in vitro and in vivo. Trastuzumab alone showed almost no cytotoxicity to GBC cells with originally low HER2 gene amplification. Sequential therapy with chemotherapy followed by trastuzumab showed superiority over reverse sequential chemotherapy (P<0.05), concurrent combined chemotherapy (P<0.05), chemotherapy alone (P<0.05), and trastuzumab alone (P<0.05) in terms of cytotoxicity. Sequential therapy with chemotherapy followed by trastuzumab nearly completely inhibited cell viability in HER2-negative GBC cells. Similar results were observed with regard to apoptosis. Western blot analysis showed that gemcitabine/5-fluorouracil increased the expressions of total and phosphorylated forms of HER2, thus enhancing the cytotoxicity of trastuzumab. In vivo study verified the results of in vitro study by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay and immunohistochemical analysis. Moreover, not only the lightest tumor bearing but also the best survival state was detected in sequential therapy with chemotherapy followed by trastuzumab group compared with other groups. Our in vivo and in vitro data suggest that sequential therapy with gemcitabine/5-fluorouracil followed by trastuzumab represents a novel and promising therapeutic strategy against HER2-negative GBC. The upregulation of phosphorylated HER2 and phosphorylated-AKT induced by gemcitabine/5-fluorouracil treatment shows that HER2/AKT pathway is triggered.
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811

Hyun Cheol Chung,Yung-Jue Bang,Charles S Fuchs,Shu-Kui Qin,Taroh Satoh,Kohei Shitara,Josep Tabernero,Eric van Cutsem,Maria Alsina,Zhu Alexander Cao,Jia Lu,Pooja Bhagia,Chie-Schin Shih,Yelena Y Janjigian,Charles S Fuchs,Eric Van Cutsem,Zhu Alexander Cao

DOI: https://doi.org/10.2217/fon-2020-0737

2021-02-01

Future Oncology

Abstract:Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combination with chemotherapy and in combination with trastuzumab. Combining pembrolizumab with trastuzumab and chemotherapy may therefore provide a benefit for patients with advanced HER2-positive gastric cancer. Here we aimed to describe the design of and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-811 study, which will evaluate the efficacy and safety of pembrolizumab or placebo in combination with trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma. Clinical trial registration: NCT03615326 ( ClinicalTrials.gov )

oncology
Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer

Y. Janjigian,A. Kawazoe,P. Weber,S. Luo,S. Lonardi,O. Kolesnik,O. Barajas,Y. Bai,L. Shen,Y. Tang,L. Wyrwicz,K. Shitara,S. Qin,E. Van Cutsem,J. Tabernero,L. Li,C. Shih,P. Bhagia,H. Chung

DOI: https://doi.org/10.1016/j.annonc.2021.06.011

IF: 51.769

2021-01-01

Annals of Oncology

Abstract:Standard-of-care (SOC) first-line therapy for HER2-positive metastatic G/GEJ cancer is trastuzumab plus chemotherapy. Adding pembrolizumab to SOC showed promising efficacy and manageable safety in two phase 2 studies. In the ongoing global, randomized, double-blind phase 3 KEYNOTE-811 study, we are assessing whether adding pembrolizumab to trastuzumab and chemotherapy improves efficacy versus trastuzumab and chemotherapy alone for participants with HER2-positive metastatic G/GEJ cancer (NCT03615326). Eligible participants with previously untreated, unresectable or metastatic HER2-positive G/GEJ cancer and ECOG PS 0 or 1 are allocated 1:1 to receive pembrolizumab 200 mg IV Q3W or placebo IV Q3W for up to 2 years or until intolerable toxicity or PD; all participants also receive trastuzumab and investigator’s choice of 5-fluorouracil and cisplatin (FP) or capecitabine and oxaliplatin (CAPOX) at standard doses. Accrual to the global cohort, planned for 692 participants, is almost complete. Response and PD are assessed per RECIST v1.1 by blinded, independent central review. PFS and OS are the dual primary endpoints. ORR and DOR are secondary endpoints. The protocol-specified first interim analysis was to occur when the first 260 participants had at least 8.5 months follow-up and assessed whether ORR was significantly improved in the pembrolizumab versus placebo arm; the superiority boundary was P = 0.002. The difference in ORR was calculated using the Miettinen and Nurminen method stratified by the randomization stratification factors of geographic region, PD-L1 status, and chemotherapy choice. The efficacy population included the first 264 participants enrolled. The safety population included all enrolled participants who received study treatment as of the June 17, 2020, data cutoff (N = 433). In the efficacy population, 133 participants were randomized to pembrolizumab + SOC, 131 to placebo + SOC; CAPOX was chosen for 87.1%, and median study follow-up was 12.0 months (range, 8.5-19.4). Confirmed ORR (95% CI) was 74.4% (66.2-81.6) for pembrolizumab + SOC vs. 51.9% (43.0-60.7) for placebo + SOC (difference, 22.7% [95% CI, 11.2-33.7], P = 0.00006); CR rate was 11.3% vs. 3.1% and DCR was 96.2% vs. 89.3%. Median (range) DOR was 10.6 months (1.1+ to 16.5+) for the pembrolizumab arm and 9.5 months (1.4+ to 15.4+) for the placebo arm; estimated DOR ≥6 months and ≥9 months was 70.3% vs. 61.4% and 58.4% vs. 51.1%, respectively. In the safety population, 217 participants received pembrolizumab + SOC and 216 received placebo + SOC. AEs were grade 3-5 in 57.1% of participants in the pembrolizumab arm vs. 57.4% in the placebo arm, led to death in 3.2% vs. 4.6%, and led to discontinuation of any drug in 24.4% vs. 25.9%. The combination of pembrolizumab, trastuzumab, and chemotherapy provides a substantial, statistically significant improvement in ORR compared with placebo, trastuzumab, and chemotherapy as first-line therapy for HER2-positive, metastatic G/GEJ cancer. Along with the durability of responses and the manageable safety profile, these initial data support pembrolizumab plus trastuzumab and chemotherapy as a possible new treatment option for HER2-positive, metastatic G/GEJ cancer.
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Yelena Y. Janjigian,Akihito Kawazoe,Patricio Yañez,Ning Li,Sara Lonardi,Oleksii Kolesnik,Olga Barajas,Yuxian Bai,Lin Shen,Yong Tang,Lucjan S. Wyrwicz,Jianming Xu,Kohei Shitara,Shukui Qin,Eric Van Cutsem,Josep Tabernero,Lie Li,Sukrut Shah,Pooja Bhagia,Hyun Cheol Chung

DOI: https://doi.org/10.1038/s41586-021-04161-3

IF: 64.8

2021-12-15

Nature

Abstract:Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal junction adenocarcinomas1–3. More than a decade ago, combination therapy with the anti-HER2 antibody trastuzumab and chemotherapy became the standard first-line treatment for patients with these types of tumours4. Although adding the anti-programmed death 1 (PD-1) antibody pembrolizumab to chemotherapy does not significantly improve efficacy in advanced HER2-negative gastric cancer5, there are preclinical6–19 and clinical20,21 rationales for adding pembrolizumab in HER2-positive disease. Here we describe results of the protocol-specified first interim analysis of the randomized, double-blind, placebo-controlled phase III KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for unresectable or metastatic, HER2-positive gastric or gastro-oesophageal junction adenocarcinoma22 (https://clinicaltrials.gov, NCT03615326). We show that adding pembrolizumab to trastuzumab and chemotherapy markedly reduces tumour size, induces complete responses in some participants, and significantly improves objective response rate.

multidisciplinary sciences
Fe-salphen complexes from intracellular pH-triggered degradation of Fe3O4@Salphen-InIII CPPs for selectively killing cancer cells.

Shuai Xu,Jing Liu,D. Li,Liming Wang,Jia Guo,Changchun Wang,Chunying Chen

DOI: https://doi.org/10.1016/j.biomaterials.2013.10.081

IF: 14

2014-02-01

Biomaterials

Abstract:
New agents on the horizon in gastric cancer

F Lordick,K Shitara,Y Y Janjigian

DOI: https://doi.org/10.1093/annonc/mdx051

2017-08-01

Abstract:Background: Conventional cytotoxic chemotherapy has been the backbone of advanced gastric cancer treatment for decades and still represents a key element of the therapeutic armamentarium. However, only small increments in survival outcomes have been reached. A better understanding of genetic alterations and molecular signatures of gastric cancer has been reached in the last years. It will serve as a roadmap for better treatment stratification and future drug development. Materials and methods: We reviewed preclinical and clinical studies that assessed novel treatment targets and emerging drug therapies in gastric cancer. We performed research via PubMed, and the congress webpages of the American Society of Clinical Oncology, European Society of Medical Oncology and the Japanese Society of Medical Oncology. Results: HER2-targeting with trastuzumab is effective in HER2-positive metastatic gastric cancer; combined HER2 targeting strategies are being investigated. Studies assessing the role of HER2 targeting in the perioperative setting are ongoing. Novel treatment targets include inhibition of cancer stemness-related signaling pathways like STAT3. DNA damage repair and Claudin 18.2, a tight junction protein with high expression in gastric cancers are also novel molecular drug targets. Modification of the tumor microenvironment, including activation of immune response by PD-1/PD-L1 checkpoint inhibitors and stroma modification by matrix metalloproteinase-9 inhibition, led to first promising treatment results. Conclusion: Novel treatment options for gastric cancer patients are emerging. They involve novel mechanisms of action, and are based on our constantly increasing understanding of tumor biology and better molecular stratification of gastric cancer patients.
Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer

Guocheng Wang,Yan Huang,Liang Zhou,Haojun Yang,Huang Lin,Shengfang Zhou,Zhengang Tan,Jun Qian

DOI: https://doi.org/10.1016/j.critrevonc.2023.104197

IF: 6.625

2023-11-11

Critical Reviews in Oncology/Hematology

Abstract:For patients diagnosed with advanced gastric or gastroesophageal cancer (AGC) that is not amenable to surgical intervention, the standard of care for first-line treatment consists of fluoropyrimidine and platinum-based chemotherapy. The incorporation of novel agents into these standard first-line regimens could potentially improve patient prognosis; options for such augmentations include both immune-based and targeted therapy combinations. To provide a comparative analysis of these different first-line combination treatments, a network meta-analysis was conducted. Outcome measures comprised overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and grade 3-4 treatment-related adverse events (TRAEs). Data were drawn from 22 randomized controlled trials, encompassing 10,787 patients and 17 distinct treatment regimens. Our findings suggest that FGFR2b-targeted therapy, specifically when used in combination with chemotherapy (bemarituzumab_chemo), exhibited the greatest efficacy. This was followed by immunotherapy-based combination regimens (CPS ≥5, Sintilimab_chemo). Further, targeted combination therapy featuring CLAUDIN 18.2 (zolbetuximab_chemo) appeared beneficial based on individual patient characteristics. In the case of HER2-positive patients, the trastuzumab_chemo regimen is recommended, as most existing studies have excluded this subpopulation. These results have significant implications for both clinical decision-making and patient care in the realm of advanced gastric or gastroesophageal cancer treatment.

oncology,hematology
Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer

Ya-Kun Jiang,Wei Li,Ying-Yang Qiu,Meng Yue

DOI: https://doi.org/10.4251/wjgo.v16.i6.2318

2024-06-15

World Journal of Gastrointestinal Oncology

Abstract:Emerging therapeutic methods represented by targeted therapy are effective supplements to traditional first-line chemoradiotherapy resistance. Human epidermal growth factor receptor 2 (HER2 ) is one of the most important targets in targeted therapy for gastric cancer. Trastuzumab combined with chemotherapy has been used as the first-line treatment for advanced gastric cancer. The safety and efficacy of pertuzumab and margetuximab in the treatment of gastric cancer have been verified. However, monoclonal antibodies, due to their large molecular weight, inability to penetrate the blood-brain barrier, and drug resistance, lead to decreased therapeutic efficacy, so it is necessary to explore the efficacy of other HER2 -targeting therapies in gastric cancer. Small-molecule tyrosine kinase inhibitors, such as lapatinib and pyrrotinib, have the advantages of small molecular weight, penetrating the blood-brain barrier and high oral bioavailability, and are expected to become the drugs of choice for perioperative treatment and neoadjuvant therapy of gastric cancer after validation by large-scale clinical trials in the future. Antibo-drug conjugate, such as T-DM1 and T-DXd, can overcome the resistance of monoclonal antibodies despite their different mechanisms of tumor killing, and are a supplement for the treatment of patients who have failed the treatment of monoclonal antibodies such as trastuzumab. Therefore, after more detailed stratification of gastric cancer patients, various gastric cancer drugs targeting HER2 are expected to play a more significant role.

oncology,gastroenterology & hepatology
Trastuzumab Plus Docetaxel and Capecitabine for First-Line Treatment of Her2-positive Advanced Gastric Cancer: A Phase II, Multi-Center, Open-Label, Singlearm Study.

Feng Wang,Tian Shu Liu,Xianglin Yuan,Kangsheng Gu,Ying Yuan,Yanhong Deng,Jian-Ming Xu,Yu-Xian Bai,Ying Wang,Wangjun Liao,He-Long Zhang,Feng Bi,Bang-Mao Wang,Zhixiang Zhuang,Huiyan Luo,Rui-hua Xu

DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.4045

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:4045Background: Gastric cancer (GC) is one of the most common tumors in China. The ToGA study has shown trastuzumab in combination with fluoropyrimidine plus cisplatin prolonged overall survival (O...
HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles

Brian C Grieb,Rajiv Agarwal

DOI: https://doi.org/10.1007/s11864-021-00884-7

2021-08-23

Abstract:Gastric and gastroesophageal junction (GEJ) cancers represent the third leading cause of malignancy-associated death worldwide. Approximately 15-20% of these adenocarcinomas overexpress the human epidermal growth factor receptor 2 (HER2), a pro-proliferative receptor tyrosine kinase that has been therapeutically exploited in other disease contexts. The landmark ToGA trial demonstrated that trastuzumab, an anti-HER2 antibody, could improve overall survival for patients with HER2 overexpressing advanced gastric and GEJ adenocarcinomas. In the ensuing decade, great effort has been made to refine and expand this therapeutic strategy through a variety of avenues including optimization of chemotherapy backbones, identifying potential synergy with immune checkpoint inhibition, deployment of alternative HER2-targeted antibodies, use of small molecule inhibitors, and development of HER2-directed antibody drug conjugates. While the results of these efforts have had variable success, they have led to a greater understanding of the mechanisms of both primary and acquired resistance to HER2-directed therapies, laying the groundwork for future investigations. Recently, KEYNOTE-811 and DESTINY-Gastric01 have led to the FDA approvals of pembrolizumab in combination with trastuzumab and chemotherapy in the 1st-line advanced setting and trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki) in the 2nd-line setting, respectively. Herein, we review these significant works as well as discuss the ongoing investigations they have inspired, which aim to find and utilize additional means for targeting HER2 in gastric and GEJ cancers.
Liposomal eribulin (E7389-LF) plus nivolumab: a potential treatment option for patients with advanced gastric cancer?

Ali Raza Shaikh,Daniel Lin

DOI: https://doi.org/10.21037/jgo-24-415

2024-11-02

Journal of Gastrointestinal Oncology

Abstract:Ali Raza Shaikh, Daniel Lin Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Thomas Jefferson University, Philadelphia, PA, USA Comment on: Kawazoe A, Yamamoto N, Sugimoto N, et al . Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort. Clin Cancer Res 2024;30:1264-72. Keywords: Chemotherapy; immunotherapy; gastric cancer; nivolumab; liposomal eribulin Submitted Jun 01, 2024. Accepted for publication Sep 11, 2024. Published online Oct 21, 2024. doi: 10.21037/jgo-24-415 Gastric cancer remains the fifth most commonly diagnosed malignancy and a leading cause of cancer-related death worldwide, with an anticipated rise in disease burden to approximately 1.8 million new cases and 1.3 million deaths by the year 2040 (1). In the United States, there were estimated 26,500 new cases and 11,130 cancer-associated deaths in 2023 (2). Approximately one-third of new gastric cancer cases are unfortunately metastatic at diagnosis (2). The average five-year overall survival (OS) of all patients diagnosed with gastric cancer is less than 40%; however, the survival rate decreases to 7% if presenting with distant metastatic disease (2). Moreover, among patients with localized disease who are able to undergo curative-intent gastrectomy, more than one-third will still recur, with most recurrences occurring during the first two years after surgical resection, and the most common site of recurrence being distant (3). Therefore, improvements in therapies are strongly needed to improve survival outcomes. Over the past several years, the therapeutic landscape for advanced unresectable or metastatic gastric cancer has been significantly advanced by the incorporation of immune checkpoint inhibitor (ICI) therapy and molecular targeted agents into systemic treatment approaches. First-line strategies are presently informed by upfront molecular characterization of tumor tissue, including testing for microsatellite instability (MSI), programmed death ligand 1 (PD-L1), and human epidermal growth factor receptor 2 (HER2). For patients whose tumors are MSI-high or PD-L1 combined positive score (CPS) positive (≥5) and HER2-negative, the treatment paradigm consists of a doublet of cytotoxic chemotherapy, including a fluoropyrimidine [5-fluorouracil (5-FU) or capecitabine] plus platinum (oxaliplatin typically preferred over cisplatin due to more favorable toxicity profile) combined with an anti-programmed death 1 (PD-1) monoclonal antibody (mAb). The CheckMate 649 study demonstrated that in previously untreated patients with advanced unresectable or metastatic esophageal, gastroesophageal junction (GEJ) and gastric adenocarcinoma, the addition of nivolumab to FOLFOX (5-FU plus oxaliplatin) or CAPOX (capecitabine plus oxaliplatin) chemotherapy compared with FOLFOX or CAPOX alone improved OS [13.8 vs. 11.6 months, hazard ratio (HR) =0.80, 95% confidence interval (CI): 0.68–0.94], progression-free survival (PFS) (HR =0.77, 95% CI: 0.68–0.87), and overall response rate (ORR) (60% vs. 45%) in all randomized patients, with a larger magnitude of OS benefit (14.4 vs. 11.1 months, HR =0.71, 95% CI: 0.59–0.86) observed in patients with higher PD-L1, CPS ≥5 (4). Although the combination of fluoropyrimidine and platinum chemotherapy plus nivolumab received Food and Drug Administration (FDA) approval for all patients with advanced HER2-negative gastroesophageal adenocarcinoma in the frontline setting regardless of PD-L1 CPS score, additional analyses have called into question its benefit in patients with low PD-L1 expression (CPS <5) (5). Consequently, given the clearer benefit observed in patients with higher PD-L1 CPS score, current expert society guidelines recommend the addition of nivolumab to chemotherapy for patients with PD-L1 CPS ≥5 (6). The pivotal Trastuzumab for Gastric Cancer (ToGA) trial initially established HER2-directed therapy with trastuzumab in combination with fluoropyrimidine and platinum chemotherapy in the frontline setting for patients with HER2 overexpression, which comprise about 30% of the patient population (7). Given the potential for targeted antibody therapy combined with immunotherapy to improve immune cell filtration and T cell response, the phase III KEYNOTE 811 study, which investigated the addition of pembrolizumab to first-line trastuzumab plus fluoropyrimidine and platinum chemotherapy in patients with gastric and GEJ adenocarcinoma, demonstrated marked improvement in ORR (72.6% vs. 59.8%) with the addition of pembrolizumab, and PFS benefit primarily observed in patients with PD-L1 CPS ≥1 [10.0 vs. 8.1 months, HR =0.72, 95% CI: 0.60–0.87], with pending results on OS (8). Options for later lines of treatment for patients with gastric or GEJ adenocarcinoma with -Abstract Truncated-

oncology,gastroenterology & hepatology
[What's new in gastric cancer?]

Michael Masetti,Sylvie Lorenzen

DOI: https://doi.org/10.1055/a-2179-0830

Abstract:In the locally advanced stage, multimodal therapies such as perioperative chemotherapy with FLOT or neoadjuvant radiochemotherapy are recommended. The integration of immunotherapy into these concepts could improve the prognosis. Phase II/III trials such as DANTE, KEYNOTE-585 and MATTERHORN show promising results in terms of pathological remissions but data on survival time extension for unselected patients are so far sobering. Immunotherapies and new targeted therapies offer hope in the palliative treatment of metastatic gastric cancer. Studies such as CheckMate-649 and KEYNOTE-859 show an improvement in survival and response rates. Currently, both pembrolizumab and nivolumab have been approved for the first-line treatment of tumors with positive PD-L1 expression. In HER2-positive tumors, the KEYNOTE-811 study showed that patients benefit from combination therapies with immune checkpoint inhibition and anti-HER2 therapies. The antibody-drug conjugate trastuzumab-deruxtecan is a promising second-line treatment option for HER2-positive tumors after treatment failure with trastuzumab.In addition, the bispecific antibody zanidatamab shows promising results in first-line treatment. New targeted therapies against CLDN18.2 and FGFR2b are showing promising results. The anti-claudin 18.2 (CLDN18.2) antibody zolbetuximab leads to improved survival compared to chemotherapy alone in patients with CLDN18.2 positive disease in first-line therapy, with approval expected in 2024.
Zolbetuximab: a potential breakthrough in the treatment landscape of gastric cancer

Rebecca Ibrahim,Khalil Saleh,Rita Khoury,Nadine Khalife,Claude Chahine,Axel Le Cesne

DOI: https://doi.org/10.2217/fon-2023-0523

2024-01-10

Future Oncology

Abstract:Keywords: cldn 18.2 gastric cancer gastro-esophageal carcinoma HER2 nivolumab targeted therapy zolbetuximab References 1. GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017 . Lancet Gastroenterol. Hepatol. 5(1), 42–54 ( 2020 ).Medline Google Scholar 2. Lordick F, Carneiro F, Cascinu S et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up . Ann. Oncol. 33(10), 1005–1020 ( 2022 ).Medline CAS Google Scholar 3. Janjigian YY, Shitara K, Moehler M et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial . Lancet 398(10294), 27–40 ( 2021 ).Medline CAS Google Scholar 4. Bang Y-J, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial . Lancet 376(9742), 687–697 ( 2010 ).Medline CAS Google Scholar 5. Gómez-Martin C, Garralda E, Echarri MJ et al. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer . J. Clin. Pathol. 65(8), 751–757 ( 2012 ).Medline Google Scholar 6. Janjigian YY, Werner D, Pauligk C et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis . Ann. Oncol. 23(10), 2656–2662 ( 2012 ).Medline Google Scholar 7. Shitara K, Bang Y-J, Iwasa S et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer . N. Engl. J. Med. 382(25), 2419–2430 ( 2020 ).Medline CAS Google Scholar 8. Janjigian YY, Kawazoe A, Yañez P et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer . Nature 600(7890), 727–730 (<span class="references__year -Abstract Truncated-

oncology
Effects on performance of perceived control over noxious noise.

E. Blechman,E. Dannemiller

DOI: https://doi.org/10.1037//0022-006X.44.4.601

1976-08-01

Journal of Consulting and Clinical Psychology

Abstract:

Can Lymphatic Filariasis Be Eliminated by 2020?

Pembrolizumab Plus Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial

Targeted Therapies in Advanced Gastric Cancer

Abstract 5129: Clinical implication of plasma ctDNA features in HER2-positive gastric cancer treated with combinations of trastuzumab & anti-PD-1 agents

Immune checkpoint inhibitors combined with HER-2 targeted therapy in HER-2 positive gastroesophageal cancer

Trastuzumab Plus Docetaxel And Capecitabine As A First-Line Treatment For Her2-Positive Advanced Gastric Or Gastroesophageal Junction Cancer: A Phase Ii, Multicenter, Open-Label, Single-Arm Study

Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells in Vitro and in Vivo

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811

Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Fe-salphen complexes from intracellular pH-triggered degradation of Fe3O4@Salphen-InIII CPPs for selectively killing cancer cells.

New agents on the horizon in gastric cancer

Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer

Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer

Trastuzumab Plus Docetaxel and Capecitabine for First-Line Treatment of Her2-positive Advanced Gastric Cancer: A Phase II, Multi-Center, Open-Label, Singlearm Study.

HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles

Liposomal eribulin (E7389-LF) plus nivolumab: a potential treatment option for patients with advanced gastric cancer?

[What's new in gastric cancer?]

Zolbetuximab: a potential breakthrough in the treatment landscape of gastric cancer

Effects on performance of perceived control over noxious noise.